OptiNose (NASDAQ:OPTN) Shares Down 2.1%

OptiNose, Inc. (NASDAQ:OPTN) traded down 2.1% during mid-day trading on Monday . The stock traded as low as $0.88 and last traded at $0.89. 504,670 shares traded hands during trading, a decline of 36% from the average session volume of 787,976 shares. The stock had previously closed at $0.91.

OptiNose Trading Down 2.1 %

The firm’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.17.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $20.49 million for the quarter, compared to analysts’ expectations of $20.81 million. As a group, sell-side analysts anticipate that OptiNose, Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 111,426 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total value of $127,025.64. Following the transaction, the chief executive officer now directly owns 1,206,978 shares in the company, valued at approximately $1,375,954.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other OptiNose news, insider Michael F. Marino III sold 49,408 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total value of $56,325.12. Following the transaction, the insider now directly owns 550,464 shares in the company, valued at approximately $627,528.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ramy A. Mahmoud sold 111,426 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the completion of the transaction, the chief executive officer now owns 1,206,978 shares in the company, valued at $1,375,954.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 167,679 shares of company stock worth $191,154. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On OptiNose

A number of hedge funds and other institutional investors have recently modified their holdings of the business. HighMark Wealth Management LLC bought a new position in shares of OptiNose during the first quarter valued at approximately $36,000. Assenagon Asset Management S.A. lifted its position in OptiNose by 139.1% during the first quarter. Assenagon Asset Management S.A. now owns 87,096 shares of the company’s stock valued at $127,000 after acquiring an additional 50,662 shares during the last quarter. Vanguard Group Inc. lifted its position in OptiNose by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock valued at $6,194,000 after acquiring an additional 62,906 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after acquiring an additional 81,233 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in OptiNose during the second quarter valued at approximately $88,000. 85.60% of the stock is currently owned by institutional investors.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.